Immune checkpoint blockade like CTLA-4 and PD-1/PD-L1 inhibitors has fueled the field of tumor immunology in thyroid cancer, highlighting both the ability of tumor–immune system treatment and the uniqueness of tumor immunotherapy (Emens et al., 2017). This evidence concerns the gene CD274 and neoplasm.